Skip to main content

LORAZE; LORAZEPAM AJS; LORAZEPAM SXP (Southern XP IP Pty Ltd)

Product name
LORAZE; LORAZEPAM AJS; LORAZEPAM SXP
Date registered
Evaluation commenced
Decision date
Approval time
249 (255 working days)
Active ingredients
lorazepam
Registration type
EOI
Indication

LORAZE; LORAZEPAM AJS; LORAZEPAM SXP (solution for injection) is now also indicated for:

  • Pre-operative medication
  • Premedication for prolonged investigations
  • The treatment of acute anxiety states, acute agitation
  • The control of status epilepticus in adults, adolescents and children. (See Section 4.2 Dose and Method of Administration)

Help us improve the Therapeutic Goods Administration site